AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension

Key Takeaways AZN's NDA for baxdrostat targets adults with uncontrolled or treatment-resistant hypertension.AZN's filing follows phase III data showing significant systolic blood pressure reductions with baxdrostat.Baxdrostat was generally well tolerated with a safety profile aligned to its mechanism of action.AstraZeneca (AZN) announced that the FDA has accepted its new drug application (NDA) for baxdrostat for treating hard-to-control hypertension.The NDA is seeking approval of baxdrostat for treating adu ...